Researchers from Cedars-Sinai Cancer analyzed patient samples and studies conducted in animal models to identify a novel role for the IL-27 signaling pathway in hepatocellular carcinoma.
Researchers at The University of Texas MD Anderson Cancer Center developed an approach to quantify tumor-specific total mRNA levels from patient tumor samples, which contain both cancer and non-cancer cells.
Mount Sinai researchers identified genes that predict a positive response to selinexor, a multiple myeloma therapy which can have serious side effects for some patients.
Researchers from the Dana-Farber Cancer Institute and the Tisch Cancer Institute at Mount Sinai Medical School showed that the COVID-19 pandemic caused substantial disruption to clinical trials for cancer treatment and care in 2021, although patient recruitment increased in 2021.
A multi-institutional study led by UNC Lineberger Comprehensive Cancer Center researchers found that diagnostic mammography results vary across racial and ethnic groups, with the rate of diagnostic accuracy highest in non-Hispanic white women and lowest in Hispanic women.
Results from the ELIANA pivotal clinical trial showed the long-term benefit of Kymriah (tisagenlecleucel) in children and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, with a maximum survival follow-up of 5.9 years.
Five-year follow-up results from the phase III CLL14 trial demonstrated that over 60% of patients with previously untreated chronic lymphocytic leukemia who had received one-year fixed-duration combination treatment of Venclyxto/Venclexta (venetoclax) plus Gazyva (obinutuzumab) continued to show longer progression-free survival and higher rates of undetectable minimal residual disease after four years off treatment.
The ongoing, open-label, single-arm, pivotal phase II FIREFLY-1 clinical trial, evaluating DAY101 (tovorafenib) as once-weekly monotherapy in patients aged 6 months to 25 years with relapsed or progressive pediatric low-grade glioma, yielded positive initial data from the first 22 patients enrolled.
NXP900 yielded positive data in a preclinical xenograft model of group 4 medulloblastoma.
People with advanced cancer who communicated their symptoms weekly using an electronic survey had about a one-third better physical function and over a 15% better control of their symptoms compared to those who were evaluated less frequently via in-person clinical visits, according to findings from a multi-state study conducted at 52 community cancer clinics.
